Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

The list of ADCs in the clinic continues to grow, bolstered by the success of first two
marketed ADCs: ADCETRIS® and Kadcyla®. Currently, there are 40 ADCs in various …

Antibody therapeutics have revolutionized the treatment of cancer over the past two
decades. Antibodies that specifically bind tumor surface antigens can be effective …

Combining the selective targeting of tumor cells through antigen-directed recognition and
potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in …

Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …

The use of monoclonal antibodies as therapeutics requires optimizing several of their key
attributes. These include binding affinity and specificity, folding stability, solubility …

The advent of click chemistry has had a profound influence on almost all branches of
chemical science. This is particularly true of radiochemistry and the synthesis of agents for …

A robust, generally applicable, nongenetic technology is presented to convert monoclonal
antibodies into stable and homogeneous ADCs. Starting from a native (nonengineered) …

Proteins are multifunctional large organic compounds that constitute an essential
component of a living system. Hence, control over their bioconjugation impacts science at …

Antibody–drug conjugates (ADCs) have been proven clinically to be more effective anti-
cancer agents than native antibodies. However, the classical conjugation chemistries to …